X4 Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 21, 2024

XFOR$3.25-2.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss F-

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

	Year Ended December 31,
	2023	2022	2021
Operating expenses:
Research and development	72,017	61,058	50,647
Selling, general and administrative	35,505	27,020	24,702
Goodwill impairment	—	—	9,758
Gain on sale of nonfinancial assets	—	(509)	—
Total operating expenses	107,522	87,569	85,107
Loss from operations	(107,522)	(87,569)	(85,107)
Other income (expense):
Interest income	4,582	219	10
Interest expense	(5,777)	(3,993)	(3,642)
Change in fair value of warrant and derivative liabilities	7,074	1,701	(366)
Other income (expense)	554	(4,197)	426
Total other income (expense), net	6,433	(6,270)	(3,572)
Loss before provision for income taxes	(101,089)	(93,839)	(88,679)
Provision for income taxes	78	28	17
Net loss and comprehensive loss	(101,167)	(93,867)	(88,696)
Deemed dividend on Class B Warrant price reset	—	(2,546)	(13,943)
Net loss attributable to common stockholders	$(101,167)	$(96,413)	$(102,639)
Net loss per share attributable to common stockholders—basic and diluted	$(0.57)	$(1.52)	$(3.99)
Weighted average shares of common stock outstanding—basic and diluted	177,812,480	63,525,845	25,748,797
The accompanying notes are an integral part of these consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.